What Chemo-scale™ Can Reveal
Non-Invasive in vitro Chemosensitivity on Circulating Tumor Associated Cells (C-TACs) to evaluate Response / Resistance to chemotherapy drugs.
All patients who have been advised chemotherapy at any stage of the disease.
The choice of chemotherapy drugs is presently based on statistical probability of efficacy. However, a large number of patients fail on such treatments due to non-specific selection of drugs. Chemo-scale identifies the drugs which have highest probability of response and highest risk of resistance to eliminate trial and error on the patient.
C-TACs from peripheral blood are isolated and tested in vitro to observe comparative cell death when exposed to calibrated doses of cytotoxic drugs.
Peripheral blood as per DCG protocol.
Report will be available within 8-10 days.
Chemo-scale™ is an analysis of tumor cells to provide drug efficacy and resistance guidance for chemotherapy. With Chemo-scale™ analysis, we minimise the risks of therapy failure for the patient – saving money, reducing ‘trial and error’, and most importantly, intensifying the attack on cancer, not the patient.
✓Cancer is a highly heterogenous disease which has unique properties and differs in every patient and hence every patient responds differently to the same chemotherapy regimen.
✓The Chemo-scale™ approach directly tests the effect of chemotherapy/anti-cancer drugs on the patient’s tumor cells. It helps to customise the treatment plan according to the sensitivity and resistance pattern of tumor cells.
✓When armed with this information, the physician and the patient can choose the most effective chemotherapy from all available options.
✓Chemo-scale™ is the personalisation of chemotherapy by directly studying the effect of chemotherapy drugs on cells taken from a fresh biopsy sample of the tumor or Circulating Tumor Associated Cells (C-TACs) isolated from peripheral blood.
Advantages of Chemo-scale™
✓Analysis is carried out for single drugs and additional drug combinations on request.
✓It reveals cytotoxic chemotherapy drug effect on patients tumor cells.
✓It also reveals the hierarchy of these drug choices in descending order of cell death(%).
FREQUENTLY ASKED QUESTIONS
What is Chemo-scale™?
✓Chemo-scale™ is a powerful analysis performed on live tumor cells. It reveals which drugs or combinations will kill the cancer of a patient more effectively. It displaces the costly ‘trial and error’ method where the patient suffers enormously. We analyse the response of cancer to all NCCN-recommended, labelled, and off-label cytotoxic chemotherapy.
✓Chemo-scale™ enables the patient and the oncologist to make informed decisions based on actual evidence of therapy response and possible resistance.
Who will benefit?
✓Newly diagnosed patients for choosing the best among the first-line cytotoxic chemotherapy drugs.
✓For patients with cancer recurrence.
✓The test is presently available for all solid organ tumors.
How can Chemo-scale™ help?
✓Not all drugs work the same on all patients. Some of them may not prove beneficial for the patient and waste valuable time and resources at a critical point in treatment. With Chemo-scale™, there is a way to know how effective the chemotherapy will be before starting your treatment.
How is Chemo-scale™ different from other pre-treatment cancer tests?
✓Commonly available molecular tests provide information mainly about targeted therapy drugs, where cytotoxic chemotherapy is the most common first therapy.
✓Chemo-scale™ evaluates the actual response of cancer cells to cytotoxic chemotherapy drugs.
✓The key difference between other tests and Chemo-scale™ is that the best drugs are identified for treatment by studying the direct effect of drugs on tumor cells, thus enabling accurate advice.
Will Chemo-scale™ work for my specific cancer?
✓Chemo-scale™ can be used for the majority of cancers where chemotherapy is a treatment option.
How long does it take to get the results from the test?
✓The results are made available in 8-10 working days once we receive the tumor sample.
DOWNLOAD BROCHURE + SAMPLE REPORT
Please contact us for more details.